PCM
PMVP icon

Prelude Capital Management’s PMV Pharmaceuticals PMVP Stock Holding History

Prelude Capital Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-28,700
Closed -$43.3K – 1455
2024
Q4 		$43.3K Sell
28,700
-8,400
-23% -$13.3K ﹤0.01% 1151
2024
Q3 		$55.3K Sell
37,100
-97,600
-72% -$151K ﹤0.01% 1208
2024
Q2 		$218K Buy
134,700
+103,600
+333% +$187K 0.02% 950
2024
Q1 		$52.9K Buy
31,100
+7,600
+32% +$14.2K ﹤0.01% 1255
2023
Q4 		$72.8K Buy
+23,500
New +$62.2K ﹤0.01% 1052

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prelude Capital Management's PMVP Position: Q1 2025 in Review

Prelude Capital Management sold out of PMV Pharmaceuticals (PMVP) in Q1 2025, closing a stake of 28,700 shares — an estimated $43.3K sold.

Prelude Capital Management first reported a position in PMVP in Q4 2023 and held it in 5 quarters. The position peaked at $218K in Q2 2024. 55 funds tracked by Wall St. Rank hold PMVP as of Q1 2025.

  • Prelude Capital Management reported no remaining PMV Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Prelude Capital Management sold 28,700 PMV Pharmaceuticals shares in Q1 2025, an estimated $43.3K.
  • Prelude Capital Management first reported a position in PMV Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Prelude Capital Management's PMV Pharmaceuticals position peaked at $218K in Q2 2024.
  • 55 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2025.

Based on Prelude Capital Management's 13F filing for Q1 2025, filed 15 May 2025.